PRODUCT

Survodutide (10 mg Vial)

No short description available.

Quickstart Highlights

Survodutide (BI 456906) is an investigational dual GLP‑1/glucagon receptor agonist under development for obesity and metabolic liver disease[1][2]. In phase 2 trials, once‑weekly subcutaneous dosing (0.6–4.8 mg) produced dose‑dependent weight loss of 12.5–14.9% versus placebo over 46 weeks[1]. This educational protocol presents a once‑weekly subcutaneous titration approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) concentration.
Typical weekly range: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks).
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at ≤−20 °C (≤−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.

Research Indications

Weight Loss

moderate

Obesity Without Diabetes
Phase 2 trial showed 14.9% mean weight loss at 46 weeks with 4.8mg dose, 55% achieving ≥15% weight loss
Obesity With Type 2 Diabetes
Superior weight loss vs semaglutide (-8.7% vs -5.3%) at 16 weeks in head-to-head trial
Sustained Weight Management
Dual mechanism addresses both energy intake and expenditure, potentially reducing weight regain

Metabolic

effective

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 2 trial: 62% achieved MASH improvement without fibrosis worsening at 4.8mg dose
Liver Fat Reduction
63-67% achieved ≥30% liver fat reduction in MASH trial, maintained in cirrhosis patients
Type 2 Diabetes Control
Dose-dependent HbA1c reduction up to -1.6% in Phase 2 trial on metformin background

Cardiovascular

effective

Blood Pressure Reduction
Secondary endpoint in Phase 3 trials based on expected cardiovascular benefits from weight loss
Cardiovascular Risk Factors
SYNCHRONIZE-CVOT trial evaluating MACE outcomes in 4,935 high-risk participants
Metabolic Syndrome Components
Improvements in multiple parameters including waist circumference and glycemic control

Reconstitution

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Interactions

Semaglutide/Tirzepatide

Use Caution

Both are GLP-1 receptor agonists - combining may lead to excessive GLP-1 activation and increased gastrointestinal side effects. Not recommended without medical supervision.

Metformin

Compatible

No direct interaction. Can be used together as demonstrated in Phase 2 trials with type 2 diabetes patients on metformin background therapy.

SGLT2 Inhibitors

Compatible

No known interactions. Phase 3 trials allow concurrent use of SGLT2 inhibitors with appropriate monitoring of glycemic control.

Sulfonylureas

Monitor Combination

Risk of hypoglycemia when combined. Monitor blood glucose closely and consider sulfonylurea dose reduction if needed.

Insulin

Dose Dependent

May require insulin dose adjustment due to improved glycemic control. Start with lower insulin doses and titrate based on glucose monitoring.

Oral Contraceptives

Requires Timing

Delayed gastric emptying may affect absorption. Take oral contraceptives at least 1 hour before survodutide injection.

Warfarin

Monitor Combination

May affect warfarin absorption due to delayed gastric emptying. Monitor INR more frequently when initiating or changing survodutide dose.

Other Glucagon Agonists

Avoid Combination

Risk of excessive glucagon receptor activation. Do not combine with other glucagon receptor agonists.

Protocol Overview

Goal:Support metabolic improvement and weight management through dual GLP‑1/glucagon receptor activation[1][3].
Schedule:Weekly subcutaneous injections for 12–16 weeks (or longer as studied in phase 3 trials).
Dose Range:0.6–6.0 mg weekly with gradual titration over 10–12 weeks.
Reconstitution:2.0 mL per 10 mg vial (5 mg/mL) for accurate unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw.

Dosage Protocols

Start:0.6 mg weekly; increase by 0.6 mg every 2 weeks as tolerated.
Target:4.8–6.0 mg weekly by weeks 11–13.
Frequency:Once per week (subcutaneous).
Cycle Length:12–16 weeks minimum; phase 3 trials extend to 48–72 weeks.
Timing:Same day each week; rotate injection sites.

Dosage Protocols

Obesity - Conservative Start:0.6mg titrated over 24 weeksOnce weekly with 4-week intervals
Obesity - Standard Protocol:3.6-6.0mgOnce weekly
MASH Treatment:2.4-4.8mgOnce weekly
Type 2 Diabetes:0.3-2.7mgOnce weekly

Route:injectable

Storage Instructions

Lyophilized:Store at ≤−20 °C (≤−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light and avoid repeated freeze–thaw cycles.

Important Notes

Practical considerations for consistency and safety.

Use new sterile syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document weekly dose, injection site, and any tolerability observations.
For doses exceeding 100 units (1.0 mL), consider using a 1 mL Luer‑lock syringe or splitting into two injections.

Reconstitution

Remove survodutide vial from refrigerator and allow to reach room temperature (15-30 minutes)
Clean rubber stoppers of both vials with alcohol swabs
Draw prescribed amount of bacteriostatic water into syringe
Insert needle into survodutide vial at 45-degree angle
Slowly inject BAC water down the side of vial to minimize foaming
Gently swirl vial - do not shake vigorously
Allow to sit for 2-3 minutes for complete dissolution
Solution should be clear to slightly opalescent without particles
Store reconstituted solution in refrigerator immediately

Route:injectable

How It Works

Survodutide is a dual agonist that activates both GLP‑1 and glucagon receptors[1]. The GLP‑1 component enhances satiety and improves glycemic control, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation[3]. This dual mechanism is hypothesized to provide additive or synergistic effects on body weight and liver fat beyond GLP‑1 agonism alone[4]. In phase 2 trials, survodutide demonstrated substantial weight loss alongside improvements in liver enzyme markers[1][2].

Lifestyle Factors

Pair with a balanced, protein‑forward diet tailored to energy needs; GLP‑1 agonists can reduce appetite significantly.
Combine resistance training and aerobic activity to preserve lean mass during weight loss.
Stay well hydrated, especially if experiencing GI side effects.
Prioritize sleep and stress management to support metabolic health and adherence.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[10].

Benefits and Side Effects

Benefits

Dose‑dependent weight loss of 12.5–14.9% (vs placebo) over 46 weeks in phase 2 obesity trials[1].
Improvements in liver‑related biomarkers in NAFLD/NASH populations[2].
Meta‑analysis confirms consistent weight‑loss efficacy across multiple randomized controlled trials[5].
Gradual titration helps mitigate GI tolerability issues.

Side Effects

Adverse effects are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation (most common during dose escalation)[1][2].

Survodutide (10 mg Vial)

Resources

Categories

Company